STAT |
Sanofi and Regeneron encounter more payer resistance over new …
STAT Once again, Sanofi and Regeneron Pharmaceuticals are running into roadblocks trying to win over payers with their new drug for severe eczema. This time a U.K. government watchdog decided the drug would not be cost effective. Sanofi makes double EU filing for cancer and asthma drugs Sanofi responds to draft NICE guidance for its innovative atopic dermatitis drug Dupixent® ? (dupilumab)[i] Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN |
Tag Archives: Regeneron
AnaptysBio Could Rival Regeneron Pharmaceuticals, Sanofi In … – Investor’s Business Daily
Investor’s Business Daily |
AnaptysBio Could Rival Regeneron Pharmaceuticals, Sanofi In …
Investor’s Business Daily AnaptysBio (ANAB) launched to a record high Tuesday after its eczema drug appeared to outperform Regeneron Pharmaceuticals' (REGN) and Sanofi's (SNY) … Here's Why AnaptysBio Inc. Is Rocketing Higher Today AnaptysBio has game-changing results in atopic dermatitis Here's What Just Happened With AnaptysBio, Inc. (NASDAQ:ANAB) |
AnaptysBio Could Rival Regeneron Pharmaceuticals, Sanofi In … – Investor’s Business Daily
Investor’s Business Daily |
AnaptysBio Could Rival Regeneron Pharmaceuticals, Sanofi In …
Investor’s Business Daily AnaptysBio (ANAB) launched to a record high Tuesday after its eczema drug appeared to outperform Regeneron Pharmaceuticals' (REGN) and Sanofi's (SNY) … Here's Why AnaptysBio Inc. Is Rocketing Higher Today AnaptysBio Reports Positive Phase 2a Clinical Trial for Dermatitis drug AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis |